Year-end Sale % OFF 
Abstract
SESSION TITLE: Lung Cancer Treatment Posters SESSION TYPE: Original Investigation Poster PRESENTED ON: Wednesday, October 28, 2015 at 01:30 PM - 02:30 PM PURPOSE: Lung cancer is the leading cause of cancer related death in the world. Small cell lung cancer (SCLC) is an aggressive form of lung cancer with poor clinical course. Despite using new technologies and chemotherapeutic agents, little progress has been made in prolonging survival in SCLC. Performans status (PS), stage, age, gender, number of metastatic sites, weight loss and biochemical variables, such as serum albumin, sodium, alkaline phosphatase, lactat dehidrogenase levels are used to define prognosis in SCLC. However investigations are going on for finding a beter prognostic marker. The C-kit protein, which has type 3 receptor tyrosine kinase activity has been implicated in the pathophysiology of many tumors, including SCLC. Vascular endothelial growth factor (VEGF) expression was also corrolated to an increased risk of metastatic disease and a worse survival due to the role of angiogenesis in SCLC. METHODS: In our study we aimed to evaluate VEGF and C-kit expression and relation between survival and clinical factors affecting the prognosis of 53 patients who were diagnosed with SCLC between January 2005- August 2010. The expressions of VEGF and C-kit were studied immonuhistochemically. RESULTS: The expression of VEGF was detected in 64,2% and the expression of C-kit was detected in 60,4% of the patients. The results showed that VEGF and C-kit expressions were not associated with prognostic factors and survival. A multivariate analysis was perfomed to evaluate independent prognostic role of age, weight loss, PS, serum albumin level and stage. This analysis indicated that PS (p=0.001) and serum albumin (p=0.032) level had independent prognostic value on overall survival. CONCLUSIONS: Although our results did not show any correlations we recommend that the prognostic value of VEGF and C-kit expressions, must be further investigated in prospective and large studies due to their role in pathogenesis. CLINICAL IMPLICATIONS: The role of VEGF and C-kit expressions as an important event in the pathogenesis of SCLC are still debated, and remain to be clarified whether this expressions are relevant for tumor growth and survival. Based on the available data reported in the literature, C-kit tyrosine kinase inhibitors and VEGF-targeting monoclonal antibody bevacizumab have substantial clinical benefits. As a result, to understand the prognostic value of VEGF and C-kit expressions new studies and large series needed. DISCLOSURE: The following authors have nothing to disclose: Gulen Topaloglu, Aydin Yilmaz, Funda Demirag, Yurdanur Erdogan, Sezgi Sahin Duyar, Ulkü Yilmaz No Product/Research Disclosure Information
Published Version
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
